CSL stock: Buy, hold, or sell in 2025?

Let's see what analysts are saying about this blue chip giant at the start of the year.

| More on:
Woman using a pen on a digital stock market chart in an office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

CSL Ltd (ASX: CSL) stock had an underwhelming year in 2024.

During the 12 months, the biotechnology giant's shares traded relatively flat and underperformed the market.

While this is disappointing, has it created a buying opportunity for investors in 2025? Let's find out.

CSL stock: Buy, hold, or sell in 2025?

The good news is that almost all the major brokers currently have the equivalent of buy ratings on CSL's shares at the start of 2025.

The even better news is that the general consensus is that CSL stock could generate big returns over the next 12 months.

Let's look at what a few brokers are saying about the plasma therapies leader.

Over at Morgans, its analysts have an add rating and $330.75 price target on the company's shares. This implies potential upside of almost 15% for investors from current levels.

The broker recently named CSL as one of its Best Calls to Action. It notes that these are "stocks that present compelling buying prospects right now."

Elsewhere, analysts at Macquarie have an outperform rating and $334.00 price target on CSL stock. This suggests that upside of approximately 16% is possible over the next 12 months.

In addition, the broker has previously stated its belief that CSL's shares could hit $500 within three years. This is based on its forecast for strong double-digit earnings growth for the foreseeable future thanks to the CSL Behring plasma business.

What else?

UBS is also bullish on CSL and has a buy rating and $330.00 price target on its shares, and Jarden has an overweight rating and $329.62 price target on them.

But the most bullish broker is arguably Bell Potter, which has a buy rating and $345.00 price target. This implies potential upside of almost 20% for investors in 2025.

Commenting on its buy rating, the broker said:

We expect CSL will achieve guidance of "annual double-digit earnings growth" over the mid-term driven largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business units do face near-term headwinds (reduced flu market demand and generic iron competition), these two units combined only contribute less than a third of total earnings.

CSL continues to be a high quality, global operator with a multi-year gross margin recovery well underway to drive earnings expansion. The stock is currently trading at a 12m forward PE 27% and 19% below 5- and 10-year averages, respectively.

Overall, this could make the biotech giant one to consider this year.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Young businesswoman sitting in kitchen and working on laptop.
Broker Notes

Is the ResMed share price still cheap? What the numbers say

Let's see what analysts are saying about this blue chip as it nears a 52-week high.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Broker Notes

What does Macquarie think REA shares are worth?

Top broker Macquarie has reviewed its rating and price target on REA shares.

Read more »

Woman checking out new TVs.
Broker Notes

Does JP Morgan think JB Hi-Fi shares can keep rising?

The retailer is up 16% for the year to date.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Broker Notes

Should you buy CBA, Telstra, and Wesfarmers shares?

Let's see what analysts are saying about these blue chips.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Broker Notes

3 of the best ASX stocks to buy now with $2,500

These shares are highly rated by the team at Bell Potter.

Read more »

A man in suit and tie is smug about his suitcase bursting with cash.
Broker Notes

2 big-name ASX 200 shares brokers rate as top buys

Let's see which shares could be in the buy zone right now.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »